Novo Nordisk

In 1923, a Nobel laureate's diabetic wife made a request that would reshape modern medicine. Marie Krogh urged her husband August to travel to Canada and secure rights to produce insulin in Denmark. Two years after its discovery, this life-saving hormone remained largely inaccessible to European patients. The Kroghs saw an opportunity to change that.

Their mission sparked the creation of two small Danish companies that began producing insulin from animal pancreases. This was the humble genesis of Novo Nordisk, now a $300 billion pharmaceutical empire and Europe's most valuable company.

The early days demanded persistence through complexity. Extracting insulin from pig and cattle pancreases was a laborious process with limited yields. Resources were scarce. But the team persevered, driven by a mission that transcended profit — saving lives.

The breakthrough came in 1925 with the Novo Syringe. Before this innovation, patients required medical assistance for every insulin injection. The syringe changed everything. Diabetics could now self-administer their medication, transforming from dependent patients into autonomous managers of their condition.

This single product decision revealed a core principle that would guide the company for the next century: focus on the patient experience, not just the drug.

Success bred competition. Two Danish insulin producers emerged: Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. For decades, they competed fiercely while the global insulin market expanded around them.

In the 1970s, an existential threat emerged. Synthetic human insulin threatened to make animal-derived insulin obsolete overnight. Both Danish companies faced a stark choice: adapt or die.

They chose adaptation. Hard.

Both companies invested heavily in biotechnology, racing to develop synthetic alternatives to their core product. The transition was costly and uncertain, but it preserved their market position as the insulin landscape evolved.

In 1982, Novo began experimenting with a hormone called GLP-1, extracting it from pig pancreases for diabetes research. Initial tests on diabetic pigs showed promise. But when human trials began, researchers observed something unexpected.

"The test subjects couldn't finish the meal. They weren't hungry," ABC News later reported.

This accidental discovery of appetite suppression would remain dormant for decades. But it planted the seed for what would eventually become Novo Nordisk's most valuable product line.

In 1989, the two competing Danish companies merged to form Novo Nordisk. The consolidation eliminated domestic competition while creating a more formidable global player. The merged entity maintained laser focus on diabetes care while expanding into related areas: obesity, hemophilia, and rare endocrine disorders.

This wasn't diversification for its own sake. Each expansion connected logically to the company's core competency in metabolic medicine.

The real transformation arrived in 2017 with FDA approval of Ozempic for diabetes treatment. Four years later, a higher-dose version called Wegovy gained approval for weight loss.

The results were staggering. Clinical trials showed that patients on the higher dose lost 15% of their body weight over 18 months, compared to 2% on placebo. Suddenly, Novo Nordisk possessed the first truly effective pharmaceutical solution for obesity — a condition affecting over 40% of American adults.

Demand exploded. Supply chains strained. The company's market capitalization surged past $300 billion, making it more valuable than Tesla or ASML.

Novo Nordisk's ownership structure enables its long-term thinking. The Novo Nordisk Foundation holds controlling shares, shielding management from quarterly earnings pressure. This structure gave former CEO Mads Øvlisen "the latitude and permission to think long term," as he put it.

During economic downturns, Øvlisen refused layoffs, instead relocating employees within the company. His reasoning: "I believe that each and every person in the company has a unique possibility of contributing to that company's progress."

This approach built loyalty and attracted top talent while preserving institutional knowledge through difficult periods.

The NovoPen's development illustrates the company's approach to innovation. Engineers didn't look within medical devices for inspiration. They studied ballpoint pens and mechanical pencils, then adapted those mechanisms for insulin delivery.

This cross-industry pollination became a recurring pattern. Solutions often came from unexpected places, requiring teams to look beyond their immediate field for breakthrough ideas.

Today, Novo Nordisk employs over 64,000 people across 80 countries, selling products in 170 nations. Yet the company's website still echoes its founding mission: "We take no pleasure in the suffering and hardships faced by people living with a chronic disease. We are committed to helping societies defeat diabetes."

A century after Marie Krogh's urgent request, that commitment remains the company's organizing principle.

The NovoPen emerged from studying everyday objects, not medical research. Breakthrough solutions often require cross-pollination of ideas from unrelated fields. Your next innovation might come from an adjacent industry's established practices.

Novo Nordisk has maintained laser focus on metabolic medicine since 1923. Even their expansion into weight loss connects directly to diabetes treatment. This concentration enabled deep expertise and market dominance within their niche.

The company's original mission — helping diabetes patients — still drives decisions today. This consistency attracts talent, guides strategy, and maintains organizational identity through leadership transitions.

The foundation ownership model protects Novo Nordisk from short-term market pressures. Your company's ownership and governance structure should enable the right kind of decision-making for your industry and time horizon.

During downturns, Øvlisen relocated rather than eliminated employees. This approach preserved institutional knowledge, built loyalty, and maintained the company's reputation as an employer of choice. Talent retention becomes competitive advantage over time.

The transformation from a small Danish insulin producer to a $300 billion pharmaceutical empire illustrates how sustained focus, patient capital, and mission-driven leadership can compound over decades. Novo Nordisk's success wasn't built on pivots or rapid expansion. It emerged from doing one thing exceptionally well, then extending that expertise into adjacent opportunities.

Sometimes the most profound innovations come not from revolutionary change, but from century-long commitment to a single, worthy problem.